Cardiovascular events, all-cause mortality, decompensated cirrhosis, and other key outcomes were compared between the two groups using multivariable-adjusted Cox proportional hazards models
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, such as type 2 diabetes or hypertension
In this trial, once-weekly cagrilintide-semaglutide for 68 weeks in adults with overweight or obesity was highly effective and led to substantial and clinically meaningful weight loss, the authors concluded
While this approach is not standard protocol, it represents one strategy for managing tolerability challenges
Facilities with 503B registration produce medications under federal oversight and CGMP standards, while 503A pharmacies compound customized prescriptions under state licensing
Its essential to follow the correct dosing and preparation procedures to avoid complications